Marathon’s robust pipeline includes medications for rare neurological and movement disorders. We take potential treatments through the development and regulatory processes to benefit patients with unmet medical needs.
Compounds in our pipeline are on track to submit to the FDA as New Drug Applications (NDA) and are expected to earn approval in the next one to six years.
Marathon reinvests its profits to continually expand its pipeline of promising treatments for rare diseases.
Research and development
Investing in new rare disease treatments
Keeping medicine available for patients who need it